The Potential of Bacteriophages in the Treatment of Burn Wounds

• Authors: Diana Hoff -Lenczewska , Marek Kawecki , Justyna Glik , Agnieszka Klama-Baryła , Mariusz Nowak
• Languages of publication: EN
• Journal: Polish Journal of Surgery
• Year: 2013
• Volume: 85
• Issue: 10
• Pages: 615-618

Dates

published

1 - 10 - 2013

online

01 - 12 - 2013

Contributors

author

Diana Hoff -Lenczewska

• Centre For Burn Treatment in Siemianowice Śląskie,

author

Marek Kawecki

• Centre For Burn Treatment in Siemianowice Śląskie
• Department of Health Science, University of Technology and Humanities in Bielsko Biała

author

Justyna Glik

• Centre For Burn Treatment in Siemianowice Śląskie
• College of Applied Sciences in Ruda Śląska

author

Agnieszka Klama-Baryła

• Centre For Burn Treatment in Siemianowice Śląskie

author

Mariusz Nowak

• Centre For Burn Treatment in Siemianowice Śląskie

References

• 1. Harper DR, Enright MC: Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol 2011; 111(1): 1-7.[Crossref][PubMed]
• 2. Ahmad SI: Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med Hypotheses 2002; 58(4): 327-31.[PubMed][Crossref]
• 3. Wang J, Hu B, Xu M et al.: Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int J Mol Med 2006; 17(2): 309-17.
• 4. Lazareva EB , Smirnov SV, Khvatov VB et al.: Efficacy of bacteriophages in complex treatment of patients with burn wounds. Antibiot Khimioter 2001; 46(1): 10-14.
• 5. Popova AV, Zhilenkov EL , Myakinina VP et al.: Isolation and characterization of wide host range lyticbacteriophage AP22 infecting Acinetobacter baumannii. FEMS Microbiol Lett 2012; 332(1): 40-46.
• 6. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM: Phage treatment of human infections. Bacteriophage 2011; 1(2): 66-85.[PubMed][Crossref]
• 7. Boratyński J, Syper D, Weber-Dabrowska B et al.: Preparation of endotoxin-free bacteriophages. Cell Mol Biol Lett 2004; 9(2): 253-59.
• 8. Borysowski J, Lobocka M, Międzybrodzki R et al.: Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives. BioDrugs 2011; 25(6): 347-55.[WoS][Crossref]
• 9. Górski A, Międzybrodzki R, Borysowski J et al.: Phage as a modulator of immune responses: practical implications for phage therapy. Adv Virus Res 2012; 83: 41-71.[WoS][Crossref]
• 10. Borysowski J, Górski A: Is phage therapy acceptable in the immunocompromised host? Int JInfect Dis 2008; 12(5): 466-71.[Crossref]
• 11. Miedzybrodzki R, Fortuna W, Weber-DabrowskaB, Górski A: A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. Clin Exp Med 2009; 9(4): 303-12.[WoS][PubMed][Crossref]
• 12. Fortuna W, Miedzybrodzki R, Weber-DabrowskaB, Górski A: Bacteriophage therapy in children: facts and prospects. Med Sci Monit 2008; 14(8): RA126-32.
• 13. Górski A, Wazna E, Dabrowska BW et al.: Bacteriophage translocation. FEMS Immunol MedMicrobiol 2006; 46(3): 313-19.[Crossref]
• 14. Miedzybrodzki R, Switala-Jelen K, FortunaW et al.: Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxinstimulated polymorphonuclear leukocytes. VirusRes 2008; 131(2): 233-42.[WoS]
• 15. Verbeken G, Pirnay JP, De Vos D et al.: Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp (Warsz) 2012; 60(3): 161-72. [WoS][Crossref]

Identifiers

DOI

10.2478/pjs-2013-0092